Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap

Heart failure is a significant public health burden that differentially impacts women. Important sex- and gender-based differences in HF risk factors, presentation, and treatment exist, and the generation of high-quality evidence is critical to elucidate these differences. Despite the remarkable gro...

Full description

Saved in:
Bibliographic Details
Published in:American heart journal plus 2022-01, Vol.13, p.100093, Article 100093
Main Authors: Reza, Nosheen, Gruen, Jadry, Bozkurt, Biykem
Format: Article
Language:English
Subjects:
Clinical trials
Diversity
Female
Heart failure
Patient participation
Sex characteristics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure is a significant public health burden that differentially impacts women. Important sex- and gender-based differences in HF risk factors, presentation, and treatment exist, and the generation of high-quality evidence is critical to elucidate these differences. Despite the remarkable growth of the heart failure clinical research enterprise over the last four decades, women remain underrepresented in heart failure clinical trials relative to the population prevalence of heart failure in women. This disparity has resulted in significant knowledge gaps regarding the optimal care of women with heart failure. In this review, we summarize the existing literature regarding the participation of women in heart failure clinical trials. Additionally, we explain the evidence surrounding sex- and gender-specific barriers to enrollment in heart failure clinical trials and describe interventions that should be implemented throughout the clinical trial lifespan to achieve sex and gender parity. [Display omitted]
ISSN:2666-6022
2666-6022
DOI:10.1016/j.ahjo.2022.100093